---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-068538"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T05:07:08.773859+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Pfizer acquires Seagen for $229/share in $43B cash deal to boost oncology

## Summary
- Acquisition of Seagen for $229 per share in cash; total enterprise value approximately $43 billion.
- Seagen expected to generate ~$2.2B revenue in 2023 and contribute >$10B risk-adjusted revenue by 2030.
- Pfizer to finance with $31B new long-term debt; deal expected to be neutral to slightly accretive to adjusted EPS in 3-4 years.
- Transaction expected to close in late 2023 or early 2024, subject to shareholder vote and regulatory approvals.
- Baker Bros. Advisors, holding significant Seagen shares, entered voting agreement to support the merger.

## SEC filing metadata
- accession: 0001193125-23-068538
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000119312523068538/0001193125-23-068538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000119312523068538/d408093d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-068538
- JSON: https://secwatch.observer/filing/0001193125-23-068538.json
- Plain text: https://secwatch.observer/filing/0001193125-23-068538.txt

## Key facts
- Material Agreements
  PFIZER INC entered into Agreement and Plan of Merger with Seagen Inc. valued at $229.00 per share (effective 2023-03-12).
  - Action: entry
  - Agreement: merger
  - Counterparty: Seagen Inc.
  - Value: $229.00 per share
  - Effective: 2023-03-12
  source text: On March 12, 2023, Pfizer Inc. (“ Pfizer ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Pfizer, Seagen Inc. (“ Seagen ”) and Aris Merger Sub, Inc., a wholly owned subsidiary of Pfizer (“ Merger Sub ”), pursuant to which, among other things, Merger Sub will be merged with and into Seagen (the “ Merger ”), with Seagen surviving the Merger as a wholly owned subsidiary of Pfizer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000119312523068538/0001193125-23-068538-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.